课题基金 / 基金详情

WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?

WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?
哪种 ECD4-IG 同种型最有效地抑制病毒复制?
批准号:
9390589
负责人:
MICHAEL DAVID ALPERT
金额:
$93.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-10 至 2019-01-31

项目摘要

项目成果

MICHAEL DAVID ALPERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): We have engineered a synthetic antibody that neutralizes 100% of HIV strains. This antibody is built from the parts of CD4 and CCR5 that are recognized by HIV, and is named "eCD4-Ig." The goal of our research program is now to maximize its efficacy. A fundamental question for our effort-and for the field as a whole-is: Which isotype of IgG has the properties that are most important for suppressing viral replication? To answer this question, we will eliminate problematic features of IgG2 and IgG3 that have historically presented a barrier to their use as therapeutics in humans, and we will compare the ability of rhesus IgG1, IgG2, and IgG3 forms of eCD4-Ig to suppress SIV replication in macaques. The isotype of eCD4-Ig that most completely suppresses viral replication will be advanced to human clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
  • 批准号:
    10867558
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Process development for manufacturing eCD4-Ig
  • 批准号:
    10603836
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Glycoengineering eCD4-Ig
  • 批准号:
    10589151
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
Glycoengineering eCD4-Ig
  • 批准号:
    10549884
  • 项目类别:
  • 资助金额:
    $97.47万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL DAVID ALPERT
  • 依托单位:
海外基金